stapokibart
What stands out
- Same target as Dupixent
- Binds to IL-4 receptor, the docking point for both the IL-4 and IL-13 signals
- Injection every 2 or 3 weeks in trials
Derived from FDA substance registry · NCT06162507 · UniProt P24394 · NCT05715320 · US label: Dupixent · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Feb 24, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- Nov 26, 2025Phase 2 trial completedA Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT06116565
- Aug 6, 2025Phase 3 trial postedA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis ClinicalTrials.gov NCT07106372
- May 4, 2025Phase 3 trial postedStudy of Stapokibatrt in Children Subjects With Atopic Dermatitis ClinicalTrials.gov NCT06956196
- Jan 23, 2025Phase 3 trial completedStudy of CM310 Injection in Adolescent Subjects With Atopic Dermatis ClinicalTrials.gov NCT06277765
- Aug 2, 2024Phase 3 trial startedStudy of CM310 in Adolescent Subjects With Atopic Dermatis ClinicalTrials.gov NCT06495229
- Jul 18, 2024Phase 2 trial completedStudy of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05715320
- Jul 4, 2024Phase 1/2 trial completedStudy of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis ClinicalTrials.gov NCT06162507
- Mar 21, 2024Phase 3 trial startedStudy of CM310 Injection in Adolescent Subjects With Atopic Dermatis ClinicalTrials.gov NCT06277765
- Dec 25, 2023Phase 3 trial completedA Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05265923
- Dec 22, 2023Phase 1/2 trial startedStudy of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis ClinicalTrials.gov NCT06162507
- Dec 21, 2023Phase 2 trial startedA Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT06116565
- Oct 31, 2023Phase 3 main data collectedA Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05265923
- Jul 28, 2023Phase 2 trial completedA Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis ClinicalTrials.gov NCT05579925
- Mar 10, 2023Phase 2 trial startedStudy of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05715320
- Feb 3, 2023Phase 2 trial completedThe Study of CM310 in Patients With Atopic Dermatitis ClinicalTrials.gov NCT04893707
- Oct 7, 2022Phase 2 trial startedA Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis ClinicalTrials.gov NCT05579925
- Apr 22, 2022Phase 3 trial startedA Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05265923
- Nov 8, 2021Phase 2 trial completedSubcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) ClinicalTrials.gov NCT04805411
- Jun 7, 2021Phase 2 trial startedThe Study of CM310 in Patients With Atopic Dermatitis ClinicalTrials.gov NCT04893707
- Feb 24, 2021Phase 2 trial startedSubcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) ClinicalTrials.gov NCT04805411